Figure 2d:

Imaging and pathologic data for 63-year-old patient with PSA level, 21.2 ng/mL (21.2 μg/mL); PCa stage, T2b; and biopsy Gleason score, 7; resulting in combined MR imaging and MR spectroscopic imaging score of 3 (definite clinically significant cancer). (a) MR spectroscopic imaging (volume excitation with water and lipid suppression by means of spectral-spatial pulses; 1000/130; chemical shift imaging matrix, 16 × 8 × 8; field of view, 110 × 55 × 55 mm; spatial resolution, 6.9 mm; one signal acquired; and imaging time, 17 minutes) grid superimposed on transverse T2-weighted MR image (4000/102; echo train length, 12; field of view, 14 cm; acquisition matrix, 256 × 192; section thickness, 3 mm; no intersection gap; and four signals acquired). (b) Corresponding spectroscopic grid shows voxels (*) suspicious for cancer. (c) Histopathologic section shows Gleason score, 7 (solid line); total volume, 8.892 cm³ (clinically significant cancer). (d) IHC staining of prostatectomy specimens from tissue section shown in c for Ki-67(left), pAkt (middle), and AR (right).